HomeCompareALNA vs XYLD

ALNA vs XYLD: Dividend Comparison 2026

ALNA yields 2666.67% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALNA wins by $148430280508.30M in total portfolio value
10 years
ALNA
ALNA
● Live price
2666.67%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$148430280508.33M
Annual income
$138,233,078,461,413,420.00
Full ALNA calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — ALNA vs XYLD

📍 ALNA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALNAXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALNA + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALNA pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALNA
Annual income on $10K today (after 15% tax)
$226,666.67/yr
After 10yr DRIP, annual income (after tax)
$117,498,116,692,201,400.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, ALNA beats the other by $117,498,116,692,198,670.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALNA + XYLD for your $10,000?

ALNA: 50%XYLD: 50%
100% XYLD50/50100% ALNA
Portfolio after 10yr
$74215140254.18M
Annual income
$69,116,539,230,708,320.00/yr
Blended yield
93.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALNA right now

ALNA
Analyst Ratings
1
Buy
Consensus: Buy
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALNA buys
0
XYLD buys
0
No recent congressional trades found for ALNA or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALNAXYLD
Forward yield2666.67%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$148430280508.33M$25.3K
Annual income after 10y$138,233,078,461,413,420.00$3,219.02
Total dividends collected$147720561198.01M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ALNA vs XYLD ($10,000, DRIP)

YearALNA PortfolioALNA Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$277,367$266,666.67$10,818$1,098.39+$266.5KALNA
2$7,209,347$6,912,564.90$11,738$1,222.51+$7.20MALNA
3$175,631,950$167,917,948.81$12,774$1,364.64+$175.62MALNA
4$4,011,072,538$3,823,146,351.60$13,944$1,527.86+$4011.06MALNA
5$85,892,595,210$81,600,747,594.12$15,270$1,715.87+$85892.58MALNA
6$1,724,977,965,006$1,633,072,888,131.25$16,775$1,933.09+$1724977.95MALNA
7$32,497,077,175,537$30,651,350,752,980.08$18,490$2,184.87+$32497077.16MALNA
8$574,439,777,193,002$539,667,904,615,177.50$20,450$2,477.63+$574439777.17MALNA
9$9,530,095,370,946,888$8,915,444,809,350,376.00$22,697$2,819.19+$9530095370.92MALNA
10$148,430,280,508,326,560$138,233,078,461,413,420.00$25,280$3,219.02+$148430280508.30MALNA

ALNA vs XYLD: Complete Analysis 2026

ALNAStock

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Full ALNA Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this ALNA vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALNA vs SCHDALNA vs JEPIALNA vs OALNA vs KOALNA vs MAINALNA vs QYLDALNA vs JEPQALNA vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.